RPLND stands for retroperitoneal lymph node dissection. It is an operation to remove selected lymph nodes and surrounding tissue from the back of the abdomen, in an area called the retroperitoneum. These lymph nodes lie near major blood vessels such as the aorta and inferior vena cava, and near the kidneys, ureters and other important structures.
In testicular cancer, cancer cells may spread from the testicle to lymph nodes in this region. RPLND may be recommended in carefully selected patients to remove disease, establish the exact pathological stage, and sometimes avoid or reduce the need for chemotherapy. The role of surgery depends on the tumour type, stage, tumour-marker levels, CT findings, previous treatment and the patient’s preferences.
RPLND is a specialised cancer operation. It should be planned after review of the pathology report, tumour markers and cross-sectional imaging by a team experienced in testicular germ-cell tumours.
RPLND is most established in selected patients with non-seminoma. Depending on the clinical situation, it may be considered:
If AFP or beta-hCG remains elevated or rises after orchidectomy, this may indicate active disease beyond the testicle. Systemic treatment is often needed, and RPLND alone is generally not the appropriate first treatment. Decisions must be based on marker trends and the full clinical picture.
RPLND is not routine treatment for clinical Stage I seminoma. Standard options for Stage I seminoma commonly include surveillance, with selected alternatives discussed according to individual circumstances. For selected patients with low-volume Stage IIA/IIB seminoma, primary RPLND is an evolving de-escalation option in specialised centres or within prospective protocols; it is not a universal replacement for chemotherapy or radiotherapy. The latest guideline recommendations and the local expertise available should be considered during counselling.
Primary RPLND means the lymph-node operation is performed before chemotherapy for an appropriate indication. In selected patients, surgery can both treat the retroperitoneal disease and provide detailed histology. Some patients may not need further treatment after surgery, while others may be advised additional treatment based on the final pathology and risk of recurrence.
Post-chemotherapy RPLND is a different and often more complex operation performed when a residual retroperitoneal mass remains after chemotherapy for NSGCT. Residual masses may contain teratoma, viable cancer or scar/necrotic tissue; imaging alone may not reliably identify the tissue type. The decision to remove a residual mass depends on its size, tumour-marker results, response to treatment, histology and specialist review. This topic is covered in greater detail on the separate page about residual retroperitoneal masses after chemotherapy.
Primary RPLND and post-chemotherapy RPLND should not be treated as interchangeable procedures. The operation, technical difficulty and decision criteria may differ.
The exact operation is individualised. The surgeon uses CT scans, tumour location, the side of the original testicular tumour, previous treatment and the planned lymph-node template to determine which lymph-node areas need to be removed.
RPLND may be performed through an open operation or, in selected patients and centres, through a minimally invasive approach such as laparoscopy or robotic-assisted surgery. The best approach is not determined by the word “robotic” alone. It depends on the size and position of the mass, previous chemotherapy or surgery, vascular involvement, the required lymph-node template, surgeon experience and the need for complete cancer clearance.
A consultation should clarify why a particular approach is recommended for the individual case, what evidence supports it, and what alternatives are reasonable.
Nerve-sparing RPLND aims to preserve the sympathetic nerve pathways involved in emission and ejaculation while removing the required lymph-node tissue. Preservation is attempted only when it is oncologically safe. If tumour location or extent requires removal of involved tissue, nerve preservation may not be possible.
Nerve-sparing surgery can reduce the risk of ejaculatory dysfunction, but it cannot guarantee normal ejaculation. Patients should ask specifically about the likelihood of preserving ejaculation in their individual case, particularly if the operation is extensive or follows chemotherapy.
RPLND is a major operation near important blood vessels and abdominal structures. Potential risks include:
The individual risk profile depends on whether the operation is primary or post-chemotherapy, the size and location of disease, prior treatment and overall health. No operation can guarantee cure or preservation of ejaculation.
Testicular cancer and its treatment can affect fertility. Before RPLND or other treatment, discuss sperm banking if future biological parenthood is important to you. The timing and urgency depend on the clinical situation, and fertility counselling should not delay urgent cancer treatment.
RPLND may affect ejaculation even when erection and sexual desire remain unchanged. Ejaculation and erection are different functions. Ask the treating team what changes are possible, whether nerve-sparing is feasible, and what fertility options may remain if ejaculation is affected. Testosterone levels and function of the remaining testicle may also be reviewed when clinically indicated.
Recovery time varies with the surgical approach, extent of dissection, prior chemotherapy and any complications. The team will guide pain control, mobilisation, diet progression, wound care and return to activity. Heavy lifting and strenuous activity may need to be restricted for a period specified by the surgeon.
The final pathology report is central to the next decision. Some patients may need surveillance alone; others may be advised additional treatment. Follow-up can include clinical review, tumour markers and imaging at intervals based on the stage, pathology and treatment received. Keeping every follow-up appointment is important even when you feel well.
No. Many patients do not need RPLND. It is considered for specific stages and tumour types after reviewing markers, imaging, pathology and personal circumstances.
It can be curative in selected patients, but cure cannot be guaranteed. Some patients need chemotherapy or other treatment, and all require an appropriate follow-up plan.
Some selected patients can avoid chemotherapy, but this cannot be promised in advance. The likelihood depends on the stage and the final pathology; recurrence risk and the possibility of later chemotherapy must be discussed.
Not for every patient. Approach selection depends on disease extent, prior treatment, the required dissection and the experience of the surgical team. Cancer clearance and safety are the priorities.
Not necessarily, but ejaculation and fertility may be affected. Discuss sperm banking before treatment and ask about the chance of preserving ejaculation in your specific case.
Radical inguinal orchidectomy removes the affected testicle through a groin incision. RPLND removes selected lymph nodes in the back of the abdomen and is performed only when indicated.
No. The decision depends on the tumour type, residual mass size, marker results and response to treatment. Residual NSGCT masses are assessed differently from seminoma masses.
A consultation can review your pathology, tumour-marker trends, CT images and previous treatment to determine whether RPLND is appropriate and which surgical approach should be considered.
| Feature | Primary RPLND | Post-chemotherapy RPLND |
|---|---|---|
| When | Selected clinical stage I or low-volume stage II non-seminoma, before chemotherapy | Residual mass after chemotherapy with normal AFP and beta-hCG |
| Main aim | Staging and treatment of nodal disease | Remove residual teratoma or viable tumour |
| Surgical complexity | Usually smaller, less scarred field | Often larger, scarred and closer to vessels |
| Nerve-sparing | Often feasible | Depends on mass extent |
RPLND (retroperitoneal lymph node dissection) removes the lymph nodes around the aorta and inferior vena cava, the first landing zone for testicular cancer spread. It is used to stage or treat disease and to clear residual masses after chemotherapy.
RPLND can be done open, laparoscopically or robotically. The approach is chosen by tumour size, relation to major vessels, prior chemotherapy and surgeon experience, while the oncological template and the nerve-sparing aim stay the same.
The main risk is ejaculatory dysfunction because sympathetic nerves lie close to the nodal template. Nerve-sparing technique in suitable patients aims to preserve antegrade ejaculation, and sperm banking before treatment is still advised.
Selected videos and anonymised case summaries from Dr Swati Shah’s testicular cancer practice, shared for patient education. Every patient’s plan is individual, and a past case does not predict an individual result.
Advanced testicular cancer can still be curable, even when large residual lymph node masses remain after chemotherapy.
In this case, a 30-year-old man with a mixed germ cell tumor of the testis received systemic chemotherapy and subsequently underwent evaluation for a residual retroperitoneal lymph node mass. PET-CT showed significant residual masses measuring approximately 6 × 5 cm and 5 × 5 cm, located close to major blood vessels, including the aorta, inferior vena cava (IVC), and renal vessels.
Because of the size and location of the residual disease, surgery was technically challenging. The patient underwent exploratory laparotomy with retroperitoneal lymph node dissection (RPLND). Despite the close relationship of the tumor to the major vessels, a complete surgical resection was achieved safely, with removal of all visible residual tumor tissue.
When a testicular tumour is suspected, the surgical approach is extremely important. A scrotal incision should generally be avoided because it can disrupt the normal lymphatic drainage pathways of the testis and potentially increase the risk of local tumour contamination and altered patterns of spread.
The standard oncological procedure for a suspected testicular malignancy is high inguinal orchidectomy. Through an inguinal approach, the testis is delivered and removed along with the spermatic cord and its vascular and lymphatic pedicle, providing appropriate oncological control and allowing accurate histopathological diagnosis.
This is an important surgical principle: the first incision matters. An incorrect approach can complicate subsequent management, while the appropriate initial procedure can help ensure proper staging and treatment.
जब टेस्टिकुलर ट्यूमर (Testicular Tumour) का संदेह हो, तो सर्जरी का सही तरीका बहुत महत्वपूर्ण होता है। आमतौर पर अंडकोष (Scrotum) पर चीरा लगाने से बचना चाहिए, क्योंकि इससे अंडकोष की सामान्य लिम्फेटिक ड्रेनेज (Lymphatic drainage) प्रभावित हो सकती है और स्थानीय रूप से ट्यूमर कोशिकाओं के फैलने तथा बीमारी के फैलाव के तरीके में बदलाव का जोखिम बढ़ सकता है।
संदिग्ध टेस्टिकुलर कैंसर में मानक ऑन्कोलॉजिकल सर्जरी हाई इंग्वाइनल ऑर्किडेक्टॉमी (High Inguinal Orchidectomy) है। इसमें जांघ के ऊपरी हिस्से के पास इंग्वाइनल (Inguinal) रास्ते से अंडकोष को बाहर निकालकर, उसे स्पर्मेटिक कॉर्ड (Spermatic cord) तथा उसकी रक्त वाहिकाओं और लिम्फेटिक पेडिकल (Lymphatic pedicle) सहित हटाया जाता है। इससे उचित कैंसर सर्जरी सुनिश्चित होती है और सही हिस्टोपैथोलॉजिकल डायग्नोसिस (Histopathological diagnosis) में मदद मिलती है।
यह एक महत्वपूर्ण सर्जिकल सिद्धांत है: पहला चीरा बहुत मायने रखता है। गलत तरीके से किया गया पहला ऑपरेशन आगे के उपचार को जटिल बना सकता है, जबकि सही शुरुआती सर्जिकल प्रक्रिया बीमारी की उचित स्टेजिंग और आगे के उपचार में मदद करती है।
This video presents a compelling testimonial from a testicular cancer survivor who received life-saving treatment from Dr. Swati Shah, an expert Uro and Gynecological Oncologist. In the brief clip, the patient recounts their challenging medical journey, focusing on the critical decision-making process regarding their surgical treatment plan. Initially confronted with the difficult prospect of traditional open surgery—which typically involves a longer, more painful healing process—the patient instead opted for a state-of-the-art robotic surgery performed by Dr. Shah. The survivor shares how this advanced, minimally invasive approach made a massive difference in their overall recovery.
In the video, He speaks in Gujarati, sharing his personal experience. He explains that he initially visited the clinic because he was experiencing significant pain. After a thorough medical evaluation, he was diagnosed with cancer and advised to undergo surgical intervention. Guided by the medical expertise of Dr. Swati Shah, He confidently went ahead with the recommended operation. The surgery was a success, and he reports receiving a highly positive response to the procedure. Following the operation, his comprehensive treatment plan also included a round of chemotherapy to reduce the risk of relapse.
The patient explains that he was initially diagnosed with testicular cancer five years ago. Unfortunately, eight months prior to the video, he faced a recurrence involving a retroperitoneal lymph node. After finding Dr. Swati Shah online, he underwent a complex robotic Retroperitoneal Lymph Node Dissection (RPLND) surgery performed by her. Speaking just two months post-operation, the patient highlights his remarkably smooth and rapid recovery, noting that his follow-up medical reports have all been positive. He expresses deep gratitude and recommends Dr. Shah.
A 41-year-old man had a persistent 6 cm retroperitoneal mass at the L2–L3 level after left orchidectomy, with raised CA 19-9. The lesion abutted the left ureter and psoas muscle, and robotic RPLND was used for this complex position.
A 15-year-old boy had a 5 cm left paratesticular embryonal rhabdomyosarcoma. After inguinal orchidectomy, nerve-sparing RPLND was used for retroperitoneal nodal staging, to detect microscopic spread and guide the intensity of chemotherapy.
Details are anonymised and shown for education only.
Dr. Swati Shah operated successfully and provided excellent care throughout the treatment. She is highly skilled, compassionate, and undoubtedly the best doctor for testis cancer in Ahmedabad. We are very thankful for her guidance and expertise
I had an excellent experience with Dr. Swati Shah. She is one of the most skilled and compassionate doctors I have ever met. Her approach is very professional, and she explains every step of the treatment with great patience and clarity. The surgery was successful, and recovery was smooth under her guidance.
We had surgery done in Apollo Hospital. The doctor is very good and has done the options in a very good way. Now everything is fine.
Dr. Swati H. Shah is a uro- and gynaecologic oncosurgeon in Ahmedabad with experience in cancer surgery, robotic surgery and complex retroperitoneal tumour surgery. Her clinical and academic work includes testicular cancer surgery and RPLND, with case-based teaching and surgical education activities.
The appropriate operation for testicular cancer is individualised. A consultation should establish whether RPLND is indicated, whether an open or minimally invasive approach is suitable, and how treatment may affect fertility, ejaculation and long-term follow-up.
For an opinion about testicular cancer surgery or RPLND in Ahmedabad, bring your histopathology report, tumour-marker results, CT images and details of any treatment already received.
Shah’s Cancer & Robotic Surgery Centre, Gota, Ahmedabad | Apollo Hospital International, Ahmedabad
Appointment contact: +91 63590 11009
This page provides general educational information and does not replace an individual medical consultation. Treatment recommendations depend on the patient’s complete clinical evaluation.
Swasth Parivar: every week, practical advice on recovery, diet and warning signs. No advertising. Stop any time.
Your number is used for these updates and for the clinic to reach you. It is never sold or passed on. To stop, reply STOP on WhatsApp.
